Cisplatin-resistant cells-IN-1(化合物8)对顽固的铂类药物抗性细胞具有较高的细胞毒性。在低纳摩尔浓度范围内(IC50:0.14–1.79 μM in A549/A549-R, K562/K562-R, and MCF-7/MCF-7TamR cells),该化合物能有效降低代谢活性。
Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells.